Peptide: Hexarelin
Nuda Name: Cardiotropium
Hexarelin Benefits
- Growth hormone stimulation, cardioprotection, muscle preservation, recovery enhancement
- Growth hormone secretagogue
- Experience Level: Intermediate
FDA STATUS
Not FDA approved; research compound
PROTOCOL
Short to Medium (4 to 8 weeks)
COMMON COMBOs
CJC 1295, GHRP 2, TB 500
SIDE EFFECTS
CJC 1295, GHRP 2, TB 500
Research & Evidence
Potential Benefis
History
Hexarelin emerged in the early 1990s from research into growth hormone releasing peptides (GHRPs), synthesized as part of a series of compounds designed to stimulate growth hormone release through pathways distinct from natural growth hormone releasing hormone. This hexapeptide (His D2MeTrp Ala Trp DPhe Lys NH2) was created as a modified analog of GHRP 6 with enhanced stability and potency. Pioneering. Initial research focused on its remarkable growth hormone releasing capabilities, demonstrating potent stimulation through activation of specific secretagogue receptors in both the hypothalamus and pituitary. The revolutionary advancement in understanding came in the late 1990s when researchers discovered Hexarelin's direct cardiac effects, demonstrating that it could protect heart tissue even in growth hormone deficient animals, revealing an entirely new dimension to its potential applications. This discovery led to the identification of CD36, a cardiac receptor distinct from the growth hormone secretagogue receptor, that mediates many of Hexarelin's direct cardiovascular effects. This evolutionary understanding transformed Hexarelin from a specialized growth hormone secretagogue to what we now recognize as a dual action compound with both central hormonal and direct tissue protective properties.
How It Works
Hexarelin functions through multiple receptor systems and pathways to exert its diverse effects throughout the body. At its core, this peptide activates the growth hormone secretagogue receptor type 1a (GHSR 1a) in both the pituitary and hypothalamus, triggering a cascade of signaling that promotes pulsatile growth hormone release. This central hormonal action resembles that of the endogenous hormone ghrelin, though Hexarelin demonstrates greater potency and stability. This growth hormone stimulation subsequently influences numerous downstream pathways including metabolism, tissue repair, and cellular regeneration. What truly distinguishes Hexarelin is its direct tissue actions independent of growth hormone release. Multisystemic. In the cardiovascular system, Hexarelin binds to CD36, a class B scavenger receptor expressed on cardiomyocytes, vascular cells, and macrophages, activating protective pathways that enhance cell survival during stress conditions such as ischemia and reperfusion. The peptide demonstrates direct anti inflammatory effects in various tissues, modulating cytokine production and inflammatory signaling particularly through the interleukin 1 pathway. Hexarelin also influences broader neuroendocrine function, affecting pituitary hormones beyond growth hormone, including moderate stimulation of ACTH, prolactin, and cortisol. Rather than working through a single receptor system, Hexarelin's comprehensive activity profile stems from its ability to interact with multiple receptor types across diverse tissues, explaining its broad spectrum of effects from hormonal modulation to direct tissue protection.
How does Hexarelin differ from other growth hormone secretagogues?
What makes Hexarelin particularly valuable for cardiovascular health?
How do the timing and dosage of Hexarelin affect its results?
How does Hexarelin's effect on other hormones influence its applications?
Case Study: Michael's Performance Restoration
At 52, Michael came to us seeking to address declining energy, reduced exercise capacity, and slower recovery despite maintaining his lifelong commitment to fitness and competitive cycling. "I'm still training consistently, but my power output and endurance have declined notably over the past two years, and my recovery between sessions takes much longer than before," he explained during our initial consultation. With a family history of cardiovascular disease, he was particularly interested in supporting heart health alongside performance goals. Comprehensive testing revealed moderate reductions in growth hormone parameters along with some markers of cardiovascular stress during intensive exercise. After thorough assessment, we designed a personalized nudaVitae protocol centered around Hexarelin at 150mcg administered subcutaneously twice daily, strategically timed upon waking and before sleep to optimize hormonal response patterns. We selected Hexarelin specifically to address both his hormonal goals and cardiovascular considerations. The protocol was complemented by targeted nutritional support focusing on antioxidant and nitric oxide pathways, along with carefully structured training periodization. Revitalization. By the end of week three, Michael reported noticeable improvements in recovery between training sessions and overall energy levels. "For the first time in years, I'm waking up actually feeling refreshed and ready for the next day's training," he noted during his follow up. By week six, objective performance metrics showed an 8% increase in functional threshold power and significantly improved heart rate recovery patterns after high intensity intervals. After completing the full 10 week protocol, Michael successfully completed a challenging mountain cycling event that had felt beyond his capabilities the previous year, finishing with his best time in five years. Perhaps most significantly, follow up cardiovascular assessment showed improvements in several functional parameters, including enhanced heart rate variability and more efficient oxygen utilization during exercise. "What impressed me most wasn't just the performance improvements, but how much better my body feels during and after intense efforts," Michael reflected. His experience highlights how Hexarelin's multifaceted mechanisms can potentially support both hormonal optimization and cardiovascular function simultaneously, addressing not just the symptoms of age related decline but potentially some of the underlying physiological changes affecting performance and recovery capacity.